- Stocks
- Pharma & Healthcare
- Cohance Lifesciences
Cohance Lifesciences share price
NSE: COHANCEPharma & HealthcareDrug Manufacturers - Specialty & Generic
Cohance Lifesciences at a glance
Cohance Lifesciences (NSE: COHANCE) closed at ₹460.30 on 22 Oct 2026, down 0.25% on the day. With a market capitalisation of ₹17,363 Cr, it ranks 378th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 98.6× trailing earnings, against a return on equity of 15.8% in FY25. Over the past year the share price has fallen 46.9%. Its 52-week range is ₹266.70 (9 Mar 2026) to ₹903.40 (23 Oct 2025); the last close is 49.0% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹422 Cr (−23.1% year on year) and net profit −₹45 Cr (−197.4%), on a consolidated basis. Promoters held 57.49% of the company as of 30 Jun 2026; 94.56% of promoter shares were pledged.
Key numbers
- Market cap
- ₹17,363 CrRank 378 on NSE
- P/E (trailing)
- 98.6×
- Price to book
- 17.4×FY25
- EPS (TTM)
- ₹2.78to Q1 FY27
- ROE
- 15.8%FY25
- ROCE
- 13.4%FY25
- Debt to equity
- 0.05FY25
- Net profit margin
- 22.1%FY25
- Book value / share
- ₹66.64FY25
- 52-week high
- ₹903.4023 Oct 2025
- 52-week low
- ₹266.709 Mar 2026
- 1-year return
- −46.9%
- RSI (14-day)
- 54.8
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.25% | +2.8% | +0.5% | +5.0% | −46.9% |
Cohance Lifesciences quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹258 Cr | ₹307 Cr | ₹402 Cr | ₹549 Cr | ₹556 Cr | ₹545 Cr | ₹619 Cr | ₹422 Cr |
| Revenue YoY | +11.5% | +39.7% | +58.9% | +138.1% | +115.6% | +77.3% | +54.0% | −23.1% |
| Net profit | ₹82 Cr | ₹83 Cr | ₹39 Cr | ₹46 Cr | ₹66 Cr | ₹29 Cr | ₹8 Cr | −₹45 Cr |
| Net profit YoY | +3.0% | +78.2% | −27.4% | −23.6% | −19.0% | −65.2% | −78.5% | −197.4% |
| Net margin | 31.8% | 27.1% | 9.6% | 8.4% | 11.9% | 5.3% | 1.3% | −10.7% |
| EPS | ₹3.23 | ₹3.26 | ₹1.65 | ₹1.28 | ₹1.94 | ₹0.96 | ₹0.51 | −₹0.63 |
Cohance Lifesciences financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹834 Cr | ₹1,010 Cr | ₹1,320 Cr | ₹1,340 Cr | ₹1,051 Cr | ₹1,198 Cr |
| Operating profit | ₹356 Cr | ₹414 Cr | ₹626 Cr | ₹560 Cr | ₹406 Cr | ₹344 Cr |
| Net profit | ₹269 Cr | ₹309 Cr | ₹413 Cr | ₹411 Cr | ₹300 Cr | ₹265 Cr |
| EPS (₹) | ₹25.00 | ₹14.00 | ₹18.00 | ₹16.00 | ₹12.00 | ₹11.00 |
| Cash from operations | ₹416 Cr | ₹383 Cr | ₹330 Cr | ₹451 Cr | ₹358 Cr | ₹288 Cr |
| Total debt | ₹91 Cr | ₹36 Cr | ₹28 Cr | ₹5 Cr | ₹0 Cr | ₹6 Cr |
| Shareholders' equity | ₹845 Cr | ₹1,181 Cr | ₹1,527 Cr | ₹1,735 Cr | ₹2,051 Cr | ₹1,697 Cr |
Cohance Lifesciences shareholding pattern
| Holder | 9 May 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 66.41% | 66.41% | 57.49% | 57.49% | 57.49% | 57.49% |
| Foreign institutions | 7.38% | 7.23% | 6.51% | 6.02% | 5.59% | 6.50% |
| Domestic institutions | 11.02% | 11.40% | 20.82% | 21.57% | 21.79% | 20.09% |
| Non-institutions | 15.18% | 14.95% | 15.17% | 14.92% | 15.12% | 15.92% |
| Promoter shares pledged | — | 100.00% | 100.00% | 100.00% | 100.00% | 94.56% |
Cohance Lifesciences vs peers
The listed Pharma & Healthcare companies nearest to Cohance Lifesciences by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| GRANULESGranules India | ₹807.65 | +0.04% | +41.9% | ₹20,245 Cr | 33 | 11.7% |
| IGLIndraprastha | ₹141.87 | −0.11% | −33.1% | ₹19,601 Cr | 12.8 | 27.0% |
| COHANCECohance Lifesciences | ₹460.30 | −0.25% | −46.9% | ₹17,363 Cr | 98.6 | 15.8% |
| CAPLIPOINTCaplin Point Laboratories | ₹2,227.80 | +0.35% | +12.9% | ₹17,096 Cr | 25 | 19.3% |
| PFIZERPfizer | ₹3,712.10 | −0.93% | −30.9% | ₹16,876 Cr | 23.5 | 17.2% |
| SHILPAMEDShilpa Medicare | ₹880.90 | +4.74% | +150.3% | ₹16,836 Cr | 70.9 | 9.4% |
| ONESOURCEOnesource Specialty Pharma | ₹1,378.00 | +1.64% | −25.1% | ₹15,796 Cr | — | −1.3% |
Ask anything about Cohance Lifesciences
Pivot answers on the live chart with evidence you can check, and tests strategies against COHANCE's own history. Try: “Why has COHANCE moved over the last three months?” · “Backtest a 50-day moving-average crossover on COHANCE over five years” · “Compare COHANCE with GRANULES on margins and valuation”
Frequently asked questions about Cohance Lifesciences
What is the share price of Cohance Lifesciences today?
Cohance Lifesciences (NSE: COHANCE) last closed at ₹460.30 on 22 Oct 2026. Its 52-week high is ₹903.40 and its 52-week low is ₹266.70.
What is the market cap of Cohance Lifesciences?
Cohance Lifesciences' market capitalisation is ₹17,363 Cr (₹17,363 Cr) at the 22 Oct 2026 close, ranking 378th among the NSE companies Pivot tracks.
What is the P/E ratio of Cohance Lifesciences?
Cohance Lifesciences trades at a trailing P/E of 98.6. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 25.
What is the ROE and ROCE of Cohance Lifesciences?
Return on equity was 15.8% in FY25 and return on capital employed was 13.4% in FY25 (consolidated figures).
Is Cohance Lifesciences a debt-free company?
Cohance Lifesciences is close to debt-free: its debt-to-equity ratio was 0.05 in FY25.
What were Cohance Lifesciences' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Cohance Lifesciences reported revenue of ₹422 Cr, −23.1% year on year, and net profit of −₹45 Cr, −197.4% year on year.
How has Cohance Lifesciences stock performed over the last year?
Cohance Lifesciences' share price has fallen 46.9% over the past year, +5.0% over three months and +0.5% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Cohance Lifesciences?
As of 30 Jun 2026: promoters 57.49%, foreign institutions 6.50%, domestic institutions 20.09%, non-institutions 15.92%. 94.56% of promoter shares were pledged.
Who are Cohance Lifesciences' competitors?
The listed Pharma & Healthcare companies closest to Cohance Lifesciences by market cap are Granules India, Indraprastha, Caplin Point Laboratories, Pfizer, Shilpa Medicare and Onesource Specialty Pharma.
Is Cohance Lifesciences a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Cohance Lifesciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on COHANCE against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with C · all NSE stocks · this page as text